Joseph Kavanagh, MD
Ophthalmology · Seguin, TXNPI 1992718373
Payments from drug & device makers
Across 645 payments — averaging $797.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$395K
- Ocular Therapeutix, Inc.$79K
- Eyevance Pharmaceuticals LLC$16K
- Kala Pharmaceuticals, Inc.$5K
- AbbVie$3K
- Johnson & Johnson Surgical Vision, Inc.$3K
- plus $14K from 27 others
Across 1 payment — averaging $6735.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$7K
What the payments were for
- Consulting fees$16,07514%
- Speaking & faculty fees$68,53660%
- Travel & lodging$8,2067%
- Food & beverage$20,23918%
- Education$3640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 131 | $395,059 |
| Ocular Therapeutix, Inc. | 82 | $78,945 |
| Eyevance Pharmaceuticals LLC | 24 | $15,633 |
| Kala Pharmaceuticals, Inc. | 21 | $4,888 |
| AbbVie(2 entities) | 107 | $2,963 |
| Johnson & Johnson Surgical Vision, Inc. | 23 | $2,609 |
| NEW World Medical,inc. | 8 | $1,892 |
| Ivantis, Inc | 6 | $1,869 |
| Alcon | 34 | $1,845 |
| Biotissue Holdings Inc. | 16 | $1,178 |
| Bausch & Lomb Americas Inc. | 35 | $1,064 |
| Sun Pharmaceutical Industries Inc. | 25 | $777 |
| Amgen(2 entities) | 17 | $740 |
| Carl Zeiss Meditec USA, Inc. | 5 | $737 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $635 |
| Sight Sciences, Inc. | 12 | $593 |
| Oyster Point Pharma, Inc. | 20 | $534 |
| Novartis | 22 | $438 |
| Tarsus Pharmaceuticals, Inc. | 9 | $275 |
| Thea Pharma Inc. | 8 | $262 |
| Aerie Pharmaceuticals, Inc. | 6 | $181 |
| Regeneron | 1 | $150 |
| Dompe US, Inc. | 2 | $137 |
| Astellas Pharma US Inc | 1 | $127 |
| Eyepoint US, Inc. | 1 | $124 |
| Genentech USA, Inc. | 1 | $117 |
| Nova Eye, Inc. | 1 | $105 |
| Rxsight Inc | 2 | $90 |
| Alimera Sciences, Inc. | 2 | $83 |
| Harrow Eye, LLC | 4 | $79 |
| Shire North American Group Inc | 2 | $37 |
| Lensar, Inc. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$61,625
- Tobradex ST$14,179
- Travoprost Intraocular Implant - iDose$6,457
- Kahook Dual Blade$1,816
- Clearpath$1,816
- Ahmed Glaucoma Valve$1,816
- Streamline$1,816
- Hydrus$1,733
- Tecnis 1-piece IOL$1,497
- Tecnis 3-piece IOL$1,497
- Tecnis Symphony IOL$1,497
- Tecnis Symphony Toric IOL$1,497
- EYSUVIS$1,422
- Zerviate$1,141
- iStent Trabecular Micro-Bypass Stent System$1,000
- Prokera$550
- AmnioGraft$550
- TEPEZZA$534
- DURYSTA$457
- MIEBO$359
How this compares
$514,201 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 504 | $636,803 |
| XiidraLifitegrast | 204 | $280,880 |
| Cyclosporine | 260 | $123,843 |
| LumiganBimatoprost | 176 | $86,354 |
| RocklatanNetarsudil Mesylat/Latanoprost | 158 | $67,132 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 1,444 | $64,266 |
| Tobradex StTobramycin/Dexamethasone | 224 | $52,639 |
| ProlensaBromfenac Sodium | 131 | $46,040 |
| TyrvayaVarenicline Tartrate | 57 | $42,423 |
| CombiganBrimonidine Tartrate/Timolol | 88 | $28,016 |
| Latanoprost | 2,352 | $25,282 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 95 | $24,629 |
| RhopressaNetarsudil Mesylate | 42 | $20,968 |
| Travoprost | 157 | $20,295 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 141 | $19,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose, Alphagan P | $2,963 | $766,854793 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,064 | $310,875267 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $181 | $88,100200 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $635 | $52,962193 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $15,633 | $52,639224 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $534 | $42,42357 claims |
| AlconSimbrinza | $1,845 | $24,62995 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $777 | $19,19522 claims |
| NovartisIlevro | $438 | $13,99937 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Seguin
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.